PERSONALIZING
HEART FAILURE
CARE

 

THE
PROBLEM

6 MILLON
HEART FAILURE
PATIENTS
460,000
HIGH RISK PROCEDURES PER YR
20% (~90K)
DO NOT 
SURVIVE 
1 YEAR

These deaths occur because the current standard of care cannot accurately identify patients as high risk in advance of heart failure surgery.

OUR
BREAKTHROUGH

The first quantitative survival prediction assay for heart failure surgery.

From a simple non-invasive blood sample, the assay can predict post-operative 1-year survival with 96% accuracy.

Test Tubes_edited.jpg

HOW IT WORKS

01

SAMPLE

Using a non-invasive blood sample, MyLeukoMAP 

measures immune cell gene activity of specific genes that have been shown to predict Heart Failure survival. 

02

ANALYZE

A proprietary algorithm is used to calculate a Gene Expression Score built upon our knowledge of consistent gene expression patterns of both survivors and non-survivors.

03

PREDICT

A score is assigned to the patient relative to postoperative survival 

probability rate. This provides a clear and accurate guide to determine whether the individual patient would have be better served with surgery or with medical management.

Use of the MyLeukoMAP assay to identify the 20% High-risk patients not identified by current tools will allow cardiologists to prescribe therapy that matches individual patient survival probability. 

Use of the MyLeukoMAP assay to identify the 20% High-risk patients not identified by current tools will allow cardiologists to prescribe therapy that matches individual patient survival probability. 

A Patient with Low Survival Probability (FRP) Can Improve on Medical Therapy, Be Retested, and Then Be a Candidate for Surgery.  A Patient with High Survival Probability May be determined to be a candidate for surgery based on a Minimum 1-year Survival Benefit. 

We believe that the use of our assay to guide therapy will significantly improve the treatment of Heart Failure from the standpoint of the patient, the healthcare provider, and the healthcare system overall.

First Use of Genomics in Heart Failure 

Using Proven Technology in a New Application

 

MEET LEUKOLIFE

OUR STORY

  Brought together through Heart Failure and an eventual transplant, our team is a unique assembly of an internationally recognized doctor, healthcare leaders, members of the scientific community, marketers and a heart transplant recipient all with a shared passion to improve survival benefit in advanced heart failure patients.

OUR VISION

  Use of the MyLeukoMAP assay to identify the 20% High-risk patients not identified by current diagnostics will allow cardiologists to prescribe therapy that matches individual patient survival probability.
  We believe that the use of our assay to guide therapy will significantly improve the treatment of Heart Failure from the standpoint of the patient, the healthcare provider, and the healthcare system overall.

TECHNOLOGY

  Genomic Assay Technology is Proven and Successful. Molecular Diagnostic Assays are becoming standard-of-care in cancer diagnosis, prediction of cancer recurrence, organ transplant rejection, and selection of drugs to optimize treatment of mental illness.
  The MyLeukoMAP assay is a molecular diagnostic assay that measures gene activity from a patient's blood cells and is predictive of their fitness to recover from and survive heart failure surgery addressing a section of the population suffering from the leading cause of death.

 

DEVELOPMENT
TO LAUNCH

OUR
CLINICAL STUDY

Our validation study was completed in 2020 and now we are starting a national, multi center study to expand our data to a larger patient population, familiarize a greater number of Cardiologists to the uses for this product and to refine our shipping and product management to prepare for a large scale market launch.   

We are currently looking for investment partners who share our passion for these goals to help us realize the full potential of LeukoLifeDx.

 

LETS 
CONNECT

To schedule a meeting to discuss this meaningful breakthrough technology and potential investment, please provide your email.